Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

BACKGROUND: Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown. METHODS: Part 1 of this ongoing phase 2–3 trial was open label for dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Creech, C. Buddy, Anderson, Evan, Berthaud, Vladimir, Yildirim, Inci, Atz, Andrew M., Melendez Baez, Ivan, Finkelstein, Daniel, Pickrell, Paul, Kirstein, Judith, Yut, Clifford, Blair, Ronald, Clifford, Robert A., Dunn, Michael, Campbell, James D., Montefiori, David C., Tomassini, Joanne E., Zhao, Xiaoping, Deng, Weiping, Zhou, Honghong, Ramirez Schrempp, Daniela, Hautzinger, Kelly, Girard, Bethany, Slobod, Karen, McPhee, Roderick, Pajon, Rolando, Das, Rituparna, Miller, Jacqueline M., Schnyder Ghamloush, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127699/
https://www.ncbi.nlm.nih.gov/pubmed/35544369
http://dx.doi.org/10.1056/NEJMoa2203315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127699/
https://www.ncbi.nlm.nih.gov/pubmed/35544369
http://dx.doi.org/10.1056/NEJMoa2203315

Ejemplares similares